Telbivudine plus pegylated interferon alfa-2a in a randomized study in chronic hepatitis B is associated with an unexpected high rate of peripheral neuropathy

Journal of Hepatology

Volumn 62, Issue 1, 2015, Pages 41-47

  Marcellin, Patrick ^a   Wursthorn, Karsten ^b   Wedemeyer, Heiner ^b   Chuang, Wan Long ^c   Lau, George ^d   Avila, Claudio ^e   Peng, Cheng Yuan ^f   Gane, Edward ^g   Lim, Seng Gee ^h   Fainboim, Hugo ⁱ   Foster, Graham R ^j   Safadi, Rifaat ^k   Rizzetto, Mario ^l   Manns, Michael ^b   Bao, Weibin ^e   Trylesinski, Aldo ^e   Naoumov, Nikolai ^e  

^a BEAUJON HOSPITAL   (France)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^d Humanity and Health GI and Liver Center   (Hong Kong)

^e NOVARTIS PHARMA AG   (Switzerland)

^f CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^g AUCKLAND CITY HOSPITAL   (New Zealand)

^h NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

ⁱ HOSPITAL F J MUÑIZ   (Argentina)

^j QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^k HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^l UNIVERSITY OF TURIN   (Italy)

more..

Author keywords

Hepatitis B virus; Hepatitis surface antigen; Nucleoside analogue; Pegylated interferon; Telbivudine

Indexed keywords

ALANINE AMINOTRANSFERASE; CREATINE KINASE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; PEGINTERFERON ALPHA2A; TELBIVUDINE; VIRUS DNA; ALPHA INTERFERON; ANTIVIRUS AGENT; DRUG CARRIER; MACROGOL DERIVATIVE; RECOMBINANT PROTEIN; THYMIDINE;

ABNORMAL SENSATION; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANTIVIRAL THERAPY; ARTICLE; CHRONIC HEPATITIS; CHRONIC PATIENT; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEPATITIS B; HUMAN; IMMUNOTHERAPY; IMPOTENCE; LACTIC ACIDOSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MONOTHERAPY; MULTICENTER STUDY; MUSCLE WEAKNESS; MUSCULOSKELETAL PAIN; MYALGIA; MYOPATHY; MYOSITIS; NEUTROPENIA; PARESTHESIA; PERIPHERAL NEUROPATHY; PLASMA CONCENTRATION-TIME CURVE; POLYNEUROPATHY; RANDOMIZED CONTROLLED TRIAL; RHABDOMYOLYSIS; SENSORY NEUROPATHY; UPPER RESPIRATORY TRACT INFECTION; YOUNG ADULT; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; COMBINATION DRUG THERAPY; GENETICS; HEALTH; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; IMMUNOLOGY; INCIDENCE; METABOLISM; PERIPHERAL NERVOUS SYSTEM DISEASES; VIROLOGY;

ADULT; ANTIVIRAL AGENTS; DNA, VIRAL; DRUG CARRIERS; DRUG THERAPY, COMBINATION; FEMALE; GLOBAL HEALTH; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INCIDENCE; INTERFERON-ALPHA; MALE; PERIPHERAL NERVOUS SYSTEM DISEASES; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; THYMIDINE;

EID: 84918564103     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2014.08.021     Document Type: Article

References (23)

1. European Association for the Study of the Liver EASL clinical practice guidelines: management of chronic hepatitis B virus infection J Hepatol 57 2012 167 185
2. A.S. Lok, and B.J. McMahon Chronic hepatitis B: update 2009 Hepatology 50 2009 661 662
3. C.M. Chu, and Y.F. Liaw Chronic hepatitis B virus infection acquired in childhood: special emphasis on prognostic and therapeutic implication of delayed HBeAg seroconversion J Viral Hepat 14 2007 147 152
4. C.M. Chu, and Y.F. Liaw Predictive factors for reactivation of hepatitis B following hepatitis B e antigen seroconversion in chronic hepatitis B Gastroenterology 133 2007 1458 1465
5. Y.S. Hsu, R.N. Chien, C.T. Yeh, I.S. Sheen, H.Y. Chiou, and C.M. Chu Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B Hepatology 35 2002 1522 1527
6. M.R. Brunetto, F. Moriconi, F. Bonino, G.K. Lau, P. Farci, and C. Yurdaydin Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B Hepatology 49 2009 1141 1150
7. H.L. Janssen, M. van Zonneveld, H. Senturk, S. Zeuzem, U.S. Akarca, and Y. Cakaloglu Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial Lancet 365 2005 123 129
8. A. Kau, J. Vermehren, and C. Sarrazin Treatment predictors of a sustained virologic response in hepatitis B and C J Hepatol 49 2008 634 651
9. G.K. Lau, T. Piratvisuth, K.X. Luo, P. Marcellin, S. Thongsawat, and G. Cooksley Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B N Engl J Med 352 2005 2682 2695
10. P. Marcellin, G.K. Lau, F. Bonino, P. Farci, S. Hadziyannis, and R. Jin Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B N Engl J Med 351 2004 1206 1217
11. C.L. Lai, E. Gane, Y.F. Liaw, C.W. Hsu, S. Thongsawat, and Y. Wang Telbivudine versus lamivudine in patients with chronic hepatitis B N Engl J Med 357 2007 2576 2588
12. Y.F. Liaw, E. Gane, N. Leung, S. Zeuzem, Y. Wang, and C.L. Lai 2-Year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B Gastroenterology 136 2009 486 495
13. K. Wursthorn, M. Jung, A. Riva, Z.D. Goodman, P. Lopez, and W. Bao Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients Hepatology 52 2010 1611 1620
14. Division of AIDS. Table for grading severity of adult adverse experiences. Bethesda, MD: National Institute of Allergy and Infectious Diseases, 1992. Available from URL: http://rsc.tech-res.com/safetyandpharmacovigilance/gradingtables.aspx [Accessed October 1, 2012].
15. Wursthorn K, Jung M, Manns M, Bao W, Wedemeyer W, Avila C. Quantitative serum HBeAg monitoring during telbivudine treatment corresponds with virological outcomes. Poster 1011. In: Presented at 45th annual meeting of the European Association for the Study of the Liver (EASL). April 14-18, 2010, Vienna, Austria.
16. R. Moucari, A. Korevaar, O. Lada, M. Martinot-Peignoux, N. Boyer, and V. Mackiewicz High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: a long-term follow-up study J Hepatol 50 2009 1084 1092
17. A. Inoue, N. Tsukada, C.S. Koh, and N. Yanagisawa Chronic relapsing demyelinating polyneuropathy associated with hepatitis B infection Neurology 37 1987 1663 1666
18. R.J. Fontana Side effects of long-term oral antiviral therapy for hepatitis B Hepatology 49 2009 S185 S195
19. R.D. Fleischer, and A.S. Lok Myopathy and neuropathy associated with nucleos(t)ide analog therapy for hepatitis B J Hepatol 51 2009 787 791
20. J. Goncalves, R. Laeufle, and C. Avila Increased risk with combination of telbivudine and pegylated-interferon Alfa-2A in study CLDT600A2406, compared to uncommon rate with telbivudine monotherapy from the Novartis global database J Hepatol 50 2009 S329 Abstract #907
21. S. Kaymakoglu, D. Oguz, G. Gur, S. Gurel, E. Tankurt, and G. Ersoz Pegylated interferon Alfa-2b monotherapy and pegylated interferon Alfa-2b plus lamivudine combination therapy for patients with hepatitis B virus E antigen-negative chronic hepatitis B Antimicrob Agents Chemother 51 2007 3020 3022
22. V.P. Papadopoulos, D.N. Chrysagis, A.N. Protopapas, I.G. Goulis, G.T. Dimitriadis, and K.P. Mimidis Peginterferon alfa-2b as monotherapy or in combination with lamivudine in patients with HBeAg-negative chronic hepatitis B: a randomised study Med Sci Monit 15 2009 CR56 CR61
23. H. Wedemeyer, C. Yurdaydin, G.N. Dalekos, A. Erhardt, Y. Cakaloglu, and H. Degertekin Peginterferon plus adefovir versus either drug alone for hepatitis delta N Engl J Med 364 2011 322 331